THOMAS SCIASCIA - 11 Feb 2022 Form 4/A - Amendment Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role: Chief Medical Officer
Signature: /s/ Christopher Galletta, attorney-in-fact
Issuer symbol: TRVI
Transactions as of: 11 Feb 2022
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 01 Jul 2022, 16:44:53 UTC
Date Of Original Report: 15 Feb 2022
Next filing: 01 Jul 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRVI	Stock Option (right to buy)	Award	$0	+110,000		$0.000000	110,000	11 Feb 2022	Common Stock	110,000	$0.5110	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 11, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.
F2	This amendment to the Form 4 originally filed for the reporting person on February 15, 2022 is being filed solely to attach the power of attorney exhibit that was inadvertently excluded from the original filing.

Remarks:

Exhibit Index: 24 Power of Attorney